Biocon share price: Shares of Biocon Ltd rose 3% after Biocon Pharma received FDA approvals for cancer drugs Lenalidomide and Dasatinib, enhancing its US oncology market presence. The company also got tentative approval for Rivaroxaban. Despite recent stock declines, analysts suggest a potential 22% upside. Biocon’s Q3 profits dropped sharply due to a previous one-time gain. Biocon share price: Shares of Biocon Ltd rose 3% after Biocon Pharma received FDA approvals for cancer drugs Lenalidomide and Dasatinib, enhancing its US oncology market presence. The company also got tentative approval for Rivaroxaban. Despite recent stock declines, analysts suggest a potential 22% upside. Biocon’s Q3 profits dropped sharply due to a previous one-time gain. Economic Times
Headlines
